StemCellTreatment forBrittleBones
In response to a genetic mutation in the genes coding for collagen produced by bone-forming cells, osteogenesis imperfecta, also familiar as brittle bone disease, presents as weak, easily broken bones before birth (osteoblasts).
www.r3stemcell.com
In tissues of mesenchymal/stromal origin, such as bone marrow, human mesenchymal stem cells (MSCs) are present. Other organs have also been identified at different gestation periods to produce stem cells resembling bone marrow MSCs. Human fetal MSCs (hfMSCs), also known as fetal MSCs, have various advantages over adult MSCs, including faster cell division, better specialization capabilities, and greater capacity for tissue repair. In addition, MSCs can be separated from healthy donors, multiplied in vitro, and frozen at extremely low temperatures.
STEM CELLS AS A THERAPEUTIC TREATMENT www.r3stemcell.com
The capacity to fix genetic mutations using genetic scissors to delete particular portions of DNA is another cutting-edge method for treating osteogenesis imperfecta. Somatic cells from patients are isolated from their urine, rejuvenated in vitro to become pluripotent, genetically modified to remove the mutationcausing osteogenesis imperfecta, and differentiated into iMSCs before being transplanted. This allows for the development of personalized stem cell therapy. Such a strategy exemplifies the benefits of standardizing care.
THE FUTURE OF PERSONALIZED MEDICINE www.r3stemcell.com
